Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c. — Clinical Trial Site

41 Registered trials

9 Currently recruiting

Organisation

Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c.

Location

Ostrowiec Swietokrzyski, Poland

Identifier

ORG-100039873

Address

Ul. Ilzecka 31a, 27-400, Poland

Departments

-
8502:Cardiology
n/a
NA
Ostrowieckie Centrum Medyczne
Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c.
Ostrowieckie Centrum Medyczne s. c.
Ostrowieckie Centrum Medyczne s.c. (#1)
Ostrowieckie Centrum Medyczne spolka cywilna Anna Olech-Cudzik, Krzysztof Cudzik
Ostrowieckie Centrum Medyczne spółka cywilna Anna Olech-Cudzik, Krzysztof Cudzik
Pneumology
private site

Clinical trials at this site (41)

Search interface

A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr… Ended

2023-508663-70-00 Bronchiectasis 4 2024-06-18
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p… Ended

2023-503333-22-00 Moderate to severe controlled asthma according to Step 5 2024-01-15
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended

2022-502208-64-00 Asthma 4 2023-11-25
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2) Ended

2023-507665-25-00 Severe Eosinophilic asthma 5 2023-04-25
A 24-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4) Ended

2023-509739-22-00 Eosinophilic asthma 5 2023-04-25
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma Ended

2023-504648-33-00 Oral Corticosteroid Dependent Asthma 5 2022-07-19
A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153… Ended

2023-510172-31-00 Chronic obstructive pulmonary disease (COPD) 5 2022-04-22
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503572-24-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2022-03-02
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-507093-40-00 Chronic Obstructive Pulmonary Disease (COPD) 4 2022-01-27
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Severe asthma with an eosinophilic phenotype 5 2021-07-26
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER… Ended

2024-512012-21-00 Chronic Obstructive Pulmonary Disease 5 2021-04-08
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER… Ended

2024-512013-41-00 Chronic Obstructive Pulmonary Disease 5 2021-03-22
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended

2022-503050-39-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 5 2019-11-12